Multidimensional Assessment of Neurological Adverse Reactions Related to PD ‐1 Inhibitors: A Real‐World Pharmacovigilance Study
CNS Neuroscience & Therapeutics · 2026
DOI: 10.1002/cns.70734 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2026. Verfasst von Xiaofeng Hu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Guangyuan Central Hospital, Guangyuan, Sichuan, China. Hauptthemen laut MEDLINE: Pharmacovigilance, Immune Checkpoint Inhibitors, Programmed Cell Death 1 Receptor, Nervous System Diseases. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
PD‐1 inhibitors have revolutionized cancer immunotherapy but present significant neurological safety concerns. While clinical trials have documented neurological adverse events (nAEs), a comprehensive understanding of their patterns and risk factors remains limited. This study systematically analyzed a decade of FAERS data to investigate PD‐1 inhibitor–associated neurotoxicities.
Methods
Using FAERS data (2014–2024), we conducted disproportionality analyses (ROR, IC, PRR) to assess PD‐1 inhibitor–nAE associations. Risk factors were evaluated using logistic regression; timing analyses used log‐rank and Mann–Whitney U tests, while group comparisons used Chi‐square tests.
Results
Among 115,000 PD‐1 inhibitor–associated adverse events, 7968 (6.93%) involved nAEs, showing an increasing trend from 4.96% (Q4 2014) to 7.67% (Q1‐Q2 2024). PD‐1 inhibitors showed significant nAE signals (ROR: 1.21, 95% CI: 1.18–1.23), with cemiplimab showing the strongest association (ROR: 1.38, 95% CI: 1.18–1.62). The most common nAEs were dizziness ( N = 942, 10.3%), encephalitis ( N = 435, 4.8%), and cerebrovascular accident ( N = 451, 4.9%). Risk factors included age > 65 years (OR: 1.10), female sex (OR: 1.04), skin cancer (OR: 1.36), and nervous system cancers (OR: 1.44). The median onset time was 34 days (IQR: 12–104), with 63.8% occurring within 2 months and 59% resulting in severe outcomes.
Conclusion
This study reveals a spectrum of PD‐1 inhibitor–related neurological toxicities, mainly involving central nervous system dysfunction, providing important insights into risk patterns and timing characteristics. These findings support improved clinical monitoring practices and inform the development of personalized patient care strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Guangyuan Central Hospital, Guangyuan, Sichuan, China.
- Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P.R. China.
- Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, China.
- Dalian Medical University, Dalian, P.R. China.
- The Fourth Clinical College of China Medical University, Shenyang, China.
- Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
ORCID-Profile: Bufu Tang, Dandan Guo, Hongjie Fan
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Hu, X., Wang, X., Tang, B., Zhang, D., Cai, R., Jiang, H., Lin, Y., Song, Y., Wang, Y., Huang, H., Guo, D., Sun, X., & Fan, H. (2026). Multidimensional Assessment of Neurological Adverse Reactions Related to PD ‐1 Inhibitors: A Real‐World Pharmacovigilance Study. CNS Neuroscience & Therapeutics. https://doi.org/10.1002/cns.70734
Vancouver
Hu X, Wang X, Tang B, Zhang D, Cai R, Jiang H, et al. Multidimensional Assessment of Neurological Adverse Reactions Related to PD ‐1 Inhibitors: A Real‐World Pharmacovigilance Study. CNS Neuroscience & Therapeutics. 2026. doi:10.1002/cns.70734
BibTeX
@article{Hu2026,
author = {Hu, Xiaofeng and Wang, Xiaoli and Tang, Bufu and Zhang, Dehuan and Cai, Rongbing and Jiang, Hui and Lin, Yaling and Song, Yiheng and Wang, Yiou and Huang, Hairuo and Guo, Dandan and Sun, Xubin and Fan, Hongjie},
title = {Multidimensional Assessment of Neurological Adverse Reactions Related to PD ‐1 Inhibitors: A Real‐World Pharmacovigilance Study},
journal = {CNS Neuroscience & Therapeutics},
year = {2026},
doi = {10.1002/cns.70734}
}
EUVIMED